Sakura Bio

Sakura BioSakura Bio
Sakura Bio

Sakura Bio

Biopharmaceutical startup developing novel therapies for rare genetic diseases.

Website
DR 3.72017Active4Cambridge, United States
Rate
Advertise here

About

Sakura Bio is an innovative biotech company transforming cell therapy for cancer with effective, durable, and accessible T and NK cell treatments. Their core technology, T-Boost, enhances the potency, persistence, and resistance of reprogrammed T and NK cells against the tumor microenvironment. They aim to develop next-generation T/NK cell therapies with superior potency and durability to drive long-lasting clinical responses.
Frequently asked

What does Sakura Bio do?

Sakura Bio is an innovative biotech company transforming cell therapy for cancer with effective, durable, and accessible T and NK cell treatments. Their core technology, T-Boost, enhances the potency, persistence, and resistance of reprogrammed T and NK cells against the tumor microenvironment. They aim to develop next-generation T/NK cell therapies with superior potency and durability to drive long-lasting clinical responses.

What is Sakura Bio's revenue?

StartupHub estimates Sakura Bio's annual revenue at $681K (range $381K to $1.1M, 64% confidence), based on comparable companies in the sector.

Where is Sakura Bio headquartered?

Sakura Bio is headquartered in Cambridge, United States.

When was Sakura Bio founded?

Sakura Bio was founded in 2017.

What industry does Sakura Bio operate in?

Sakura Bio operates in Life Sciences, Biopharmaceutical, Therapeutics, Biotech, Drug Discovery, Genomics.

How many employees does Sakura Bio have?

Sakura Bio has approximately 4 people on record.

HEADCOUNT
4
DOMAIN RATING
3.7
Comments

No comments yet. Be the first to share your take.